Sarepta Therapeutics

Thank you to Marissa Penrod, founder and CEO of Team Joseph, a Duchenne patient advocacy organization, for joining us for a powerful conversation on caregiving in Duchenne. Marissa and other Duchenne caregivers shared their experiences of caring for and supporting loved ones with Duchenne. They offered insights from Team Joseph’s newly released white paper “Engulfed in Caregiving.” This resulted from a Team Joseph research project and highlights the perspectives, hardships and triumphs of a diverse group of Duchenne caregivers. Sarepta is proud to be one of the supporters of this important work. Caregivers are a critical part of the Duchenne community, and it is vital for us to continually hear and understand their perspectives. The event underscores our patient mission and commitment to the community, and we are grateful for the time and learnings. Thank you!

On our #Q3Results call, Chief Customer Officer Dallan Murray shared details on an impressive third quarter, led by the continued strength of our gene therapy launch.

On our #Q3Results call, CEO Doug Ingram discussed our third-quarter performance and shared an update on recent corporate developments.

We're excited to share our new therapy for Duchenne has been recognized as one of TIME’s Best Inventions of 2024! To learn more about Sarepta and our contributions to the rare disease community, visit: Sarepta.com #TIMEBestInventions

Are you familiar with the North Star Ambulatory Assessment (NSAA)? Sarepta’s Senior Director of Global Medical Affairs, Rachel Salazar, PT, DPT, PhD, offers a clear explanation of the clinical outcome measurement tool designed specifically for people living with #Duchenne. By rating 17 different motor skill activities, doctors can keep an eye on how a child’s functional performance changes over time due to disease progression. As Rachel shares, kids typically reach their peak score and performance around 6 years of age before entering a decline in their functional skills. “If we look at 9-year-old with Duchenne, no change or even a one-point decline is rather unexpected because this child would be typically in the steep decline phase of his disease. And if the North Star holds steady rather than declining each year, then he may be retaining abilities that he was expected to lose due to his disease.” Watch the video to learn more and view Sarepta’s fact sheet outlining the complete list of 17 measured skills. https://bit.ly/3YjVFuG #raredisease

Did you see the news that we announced the recipients of the 2024 Limb-girdle muscular dystrophy (LGMD) Grant Award Program? Created by Sarepta to help accelerate the LGMD diagnostic journey and enhance participation in genetic testing programs, this year we are awarding more than $100,000 in grant funding. Learn more about the program and read about the work of a past LGMD Grant Award Program recipient in this Newsroom article: https://bit.ly/3GKFP3D

We’re leaving #WMS2024 feeling energized by our collective progress in addressing neuromuscular disorders. Connecting with attendees – from industry peers to clinicians, scientists and caregivers – is always mission-affirming. See you next year!

We look forward to convening with industry peers this week at the 29th Annual Congress of the World Muscle Society in Prague from October 8-12. Stop by Booth #1 to say hello! #WMS2024 #Duchenne #LGMD

We’re lighting up green for limb-girdle muscular dystrophy! Today, our Genetic Therapies Center of Excellence in Columbus, Ohio is glowing with green lights for LGMD Awareness Day. We’re shining bright to show our support for the LGMD community. #LGMD2024

Today is Limb-Girdle Muscular Dystrophy Awareness Day, and we’re wearing lime green to show our support and raise awareness.💚 This year, we’re more committed than ever to supporting the LGMD community and advancing research on these rare neuromuscular diseases. Join us in going green and showing your support. #LGMDAwarenessDay #LimeGreen4LGMD